Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin‐2 after radical hepatic resection for colorectal liver metastases: 5‐year analysis
Authors:
- Andrea GardiniAGAndrea Gardini
- Giorgio ErcolaniGEGiorgio Ercolani
- Angela RiccobonARAngela Riccobon
- Laura RidolfiLaura Ridolfi
- Emanuela FlaminiEFEmanuela Flamini
- Gian Luca GraziGGGian Luca Grazi
- 21 June 2004
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 87 (1) , 46-52
Abstract
Background and Objectives: Conventional chemotherapy has not proven effective in improving long‐term results of surgery for liver metastases from colorectal cancer. We assessed the usefulness of immunotherapy with tumor infiltrating lymphocytes (TIL) plus Interleukin‐2 (IL‐2) as adjuvant treatment.Methods: Between 1995 and 1998, 47 patients were enrolled onto a prospective protocol; 25 entered the treatment group (A) and 22 entered the control group (B). All patients had undergone radical liver resection. TIL obtained from surgical specimens from group A patients were cultured and activated in vitro with IL‐2, then reinfused into the patients with IL‐2. We investigated pre‐ and post‐IL‐2 stimulation expression of T cell receptor (TCR) ζ‐ and ε‐chains, p56lck, Fas, and Fas‐L by TIL immunostaining.Results: Fourteen patients from group A (56%) received immunotherapy; 14 from group B (60%) underwent conventional chemotherapy, and the remaining 19 patients did not receive any treatment. No significant differences between the two groups were found in the actuarial and disease‐free survival (DSF) rates after 1, 3, and 5 years. After IL‐2 exposure, TCR ζ‐chain expression significantly increased (P = 0.001); An increase in TCR ε‐chain expression (P = 0.04), and p56lck (P = 0.03) was detected; TCR ε‐chain expression was significantly increased in disease‐free patients compared to those who relapsed (P = 0.04). Fas‐L expression was correlated with the TCR ε‐chain and p56lck levels (P = 0.05).Conclusions: Our data suggest that we are still a long way from being able to propose TIL + IL‐2 treatment as an effective adjuvant therapy. However, the results confirm that the biological indicators examined could play an important role in modulating immunitary response against tumor cells. J. Surg. Oncol. 2004;87:46–52.Keywords
This publication has 32 references indexed in Scilit:
- Liver Resection for Multiple Colorectal MetastasesArchives of Surgery, 2002
- Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapyImmunology Today, 1996
- Intraperitoneal Adoptive Immunotherapy of Ovarian Carcinoma with Tumor-Infiltrating Lymphocytes and Low-Dose Recombinant Interleukin-2Journal of Immunotherapy, 1994
- Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytesCancer Immunology, Immunotherapy, 1994
- Localization of111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with responseCancer, 1994
- Tumor-infiltrating lymphocytes: their phenotype, functions and clinical useCancer Immunology, Immunotherapy, 1994
- Surgical treatment of liver metastases in patients with colorectal cancerCancer, 1993
- Tumor-infiltrating lymphocytes as antitumor effector cellsBiotherapy, 1992
- A Prospective Randomized Trial of Regional Versus Systemic Continuous 5-Fluorodeoxyuridine Chemotherapy in the Treatment of Colorectal Liver MetastasesAnnals of Surgery, 1987
- Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trialsJournal of Immunological Methods, 1987